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INTRODUCTION 
PERIPHERAL NEUROPATHY 
Peripheral nerves are composed of sensory, motor, and autonomic elements. 
Diseases can affect the cell body of a neuron or its peripheral processes, 
namely the axons or the encasing myelin sheaths. Most peripheral nerves 
are mixed and contain sensory and motor as well as autonomic fibers. 
Nerves can be subdivided into three major classes: large myelinated, small 
myelinated, and small unmyelinated. Motor axons are usually large 
myelinated fibers that conduct rapidly (approximately 50 m/s). Sensory 
fibers may be any of the three types. Large-diameter sensory fibers conduct 
proprioception and vibratory sensation to the brain, while the smaller-
diameter myelinated and unmyelinated fibers transmit pain and temperature 
sensation. Autonomic nerves are also small in diameter. Thus, peripheral 
neuropathies can impair sensory, motor, or autonomic function, either singly 
or in combination. Peripheral neuropathies are further classified into those 
that primarily affect the cell body (e.g., neuronopathy or ganglionopathy), 
myelin (myelinopathy), and the axon (axonopathy). These different classes 
of peripheral neuropathies have distinct clinical and electrophysiologic 
features.  
General clinical approach to a patient suspected of having a peripheral 
neuropathy  
In approaching a patient with a neuropathy, the clinician has three main 
goals: (1) identify where the lesion is, (2) identify the cause, and (3) 
determine the proper treatment. The first goal is accomplished by obtaining 
a thorough history, neurologic examination, and electrodiagnostic and other 
laboratory studies. Despite an extensive evaluation, in approximately half of 
patients no etiology is ever found; these patients typically have a 
predominately sensory polyneuropathy and have been labeled as having 
idiopathic or cryptogenic sensory polyneuropathy (CSPN). 
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Information from the History and Physical Examination: Seven Key 
Questions  
What Systems Are Involved? 
It is important to determine if the patient's symptoms and signs are motor, 
sensory, autonomic, or a combination of these. If the patient has only 
weakness without any evidence of sensory or autonomic dysfunction, a 
motor neuropathy, neuromuscular junction abnormality, or myopathy should 
be considered. Some peripheral neuropathies are associated with significant 
autonomic nervous system dysfunction. Symptoms of autonomic 
involvement include fainting spells or orthostatic lightheadedness; heat 
intolerance; or any bowel, bladder, or sexual dysfunction. There will 
typically be an orthostatic fall in blood pressure without an appropriate 
increase in heart rate. Autonomic dysfunction in the absence of diabetes 
should alert the clinician to the possibility of amyloid polyneuropathy. 
Rarely, a pandysautonomic syndrome can be the only manifestation of a 
peripheral neuropathy without other motor or sensory findings. The majority 
of neuropathies are predominantly sensory in nature. 
What Is the Distribution of Weakness? 
Delineating the pattern of weakness, if present, is essential for diagnosis, 
and in this regard two additional questions should be answered: (1) Does the 
weakness only involve the distal extremity or is it both proximal and distal? 
and (2) Is the weakness focal and asymmetric or is it symmetric? Symmetric 
proximal and distal weakness is the hallmark of acquired immune 
demyelinating polyneuropathies, both the acute form [acute inflammatory 
demyelinating polyneuropathy (AIDP) also known as Guillain-Barré 
syndrome (GBS)] and the chronic form [chronic inflammatory 
demyelinating polyneuropathy (CIDP)]. The importance of finding 
symmetric proximal and distal weakness in a patient who presents with both 
motor and sensory symptoms cannot be overemphasized because this 
identifies the important subset of patients who may have a treatable acquired 
demyelinating neuropathic disorder (i.e., AIDP or CIDP). 
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Findings of an asymmetric or multifocal pattern of weakness narrows the 
differential diagnosis. Some neuropathic disorders may present with 
unilateral extremity weakness. In the absence of sensory symptoms and 
signs, such weakness evolving over weeks or months would be worrisome 
for motor neuron disease [e.g., amyotrophic lateral sclerosis (ALS)], but it 
would be important to exclude multifocal motor neuropathy that may be 
treatable. In a patient presenting with asymmetric subacute or acute sensory 
and motor symptoms and signs, radiculopathies, plexopathies, compressive 
mononeuropathies, or multiple mononeuropathies (e.g., mononeuropathy 
multiplex) must be considered. 
What Is the Nature of the Sensory Involvement? 
The patient may have loss of sensation (numbness), altered sensation to 
touch (hyperpathia or allodynia), or uncomfortable spontaneous sensations 
(tingling, burning, or aching). Neuropathic pain can be burning, dull, and 
poorly localized (protopathic pain), presumably transmitted by polymodal C 
nociceptor fibers, or sharp and lancinating (epicritic pain), relayed by A-
delta fibers. If pain and temperature perception are lost, while vibratory and 
position sense are preserved along with muscle strength, deep tendon 
reflexes, and normal nerve conduction studies, a small-fiber neuropathy is 
likely. This is important, as the most likely cause of small-fiber 
neuropathies, when one is identified, is diabetes mellitus or glucose 
intolerance. Amyloid neuropathy should be considered as well in such 
cases, but most of these small-fiber neuropathies remain idiopathic in nature 
despite extensive evaluation. Severe proprioceptive loss also narrows the 
differential diagnosis. Affected patients will note imbalance, especially in 
the dark. A neurologic examination revealing a dramatic loss of 
proprioception with vibration loss and normal strength should alert the 
clinician to consider a sensory neuronopathy/ganglionopathy. In particular, 
if this loss is asymmetric or affects the arms more than the legs, this pattern 
suggests a non-length-dependent process as seen in sensory neuronopathies. 
Is There Evidence of Upper Motor Neuron Involvement? 
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If the patient presents with symmetric distal sensory symptoms and signs 
suggestive of a distal sensory neuropathy, but there is additional evidence of 
symmetric upper motor neuron involvement, the physician should consider 
a disorder such as combined system degeneration with neuropathy. The 
most common cause for this pattern is vitamin B12 deficiency, but other 
causes of combined system degeneration with neuropathy should be 
considered (e.g., copper deficiency, HIV infection, severe hepatic disease, 
adrenomyeloneuropathy). 
What Is the Temporal Evolution? 
It is important to determine the onset, duration, and evolution of symptoms 
and signs. Does the disease have an acute (days to 4 weeks), subacute (4–8 
weeks), or chronic (>8 weeks) course? Is the course monophasic, 
progressive, or relapsing? Most neuropathies are insidious and slowly 
progressive in nature. Neuropathies with acute and subacute presentations 
include GBS, vasculitis, and radiculopathies related to diabetes or Lyme 
disease. A relapsing course can be present in CIDP and porphyria. 
Is There Evidence for a Hereditary Neuropathy? 
In patients with slowly progressive distal weakness over many years with 
very little in the way of sensory symptoms yet with significant sensory 
deficits on clinical examination, the clinician should consider a hereditary 
neuropathy (e.g., Charcot-Marie-Tooth disease or CMT). On examination, 
the feet may show arch and toe abnormalities (high or flat arches, 
hammertoes); scoliosis may be present. In suspected cases, it may be 
necessary to perform both neurologic and electrophysiologic studies on 
family members in addition to the patient. 
Does the Patient Have Any Other Medical Conditions? 
It is important to inquire about associated medical conditions (e.g., diabetes 
mellitus, systemic lupus erythematosus); preceding or concurrent infections 
(e.g. diarrheal illness preceding GBS); surgeries (e.g., gastric bypass and 
nutritional neuropathies); medications (toxic neuropathy); including over-
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the-counter vitamin preparations (B6); alcohol; dietary habits; and use of 
dentures (e.g., fixatives contain zinc that can lead to copper deficiency). 
Pattern Recognition Approach to Neuropathic Disorders 
Based upon the answers to the seven key questions, neuropathic disorders 
can be classified into several patterns based on the distribution or pattern of 
sensory, motor, and autonomic involvement (Table 384-2). Each pattern has 
a limited differential diagnosis. A final diagnosis is established by utilizing 
other clues such as the temporal course, presence of other disease states, 
family history, and information from laboratory studies. 
Electrodiagnostic Studies 
The electrodiagnostic (EDx) evaluation of patients with a suspected 
peripheral neuropathy consists of nerve conduction studies (NCS) and 
needle electromyography (EMG). In addition, studies of autonomic function 
can be valuable. The electrophysiologic data provides additional 
information about the distribution of the neuropathy that will support or 
refute the findings from the history and physical examination; it can confirm 
whether the neuropathic disorder is a mononeuropathy, multiple 
mononeuropathy (mononeuropathy multiplex), radiculopathy, plexopathy, 
or generalized polyneuropathy. Similarly, EDx evaluation can ascertain 
whether the process involves only sensory fibers, motor fibers, autonomic 
fibers, or a combination of these. Finally, the electrophysiologic data can 
help distinguish axonopathies from myelinopathies as well as axonal 
degeneration secondary to ganglionopathies from the more common length-
dependent axonopathies. 
NCS are most helpful in classifying a neuropathy as being due to axonal 
degeneration or segmental demyelination. In general, low-amplitude 
potentials with relatively preserved distal latencies, conduction velocities, 
and late potentials, along with fibrillations on needle EMG, suggest an 
axonal neuropathy. On the other hand, slow conduction velocities, 
prolonged distal latencies and late potentials, relatively preserved 
amplitudes, and the absence of fibrillations on needle EMG imply a primary 
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demyelinating neuropathy. The presence of nonuniform slowing of 
conduction velocity, conduction block, or temporal dispersion further 
suggests an acquired demyelinating neuropathy (e.g., GBS or CIDP) as 
opposed to a hereditary demyelinating neuropathy (e.g., CMT type 1). 
Autonomic studies are used to assess small myelinated (A-delta) or 
unmyelinated (C) nerve fiber involvement. Such testing includes heart rate 
response to deep breathing, heart rate, and blood pressure response to both 
the Valsalva maneuver and tilt-table testing, and quantitative sudomotor 
axon reflex testing. These studies are particularly useful in patients who 
have pure small-fiber neuropathy or autonomic neuropathy in which routine 
NCS are normal. 
Other Important Laboratory Information 
In patients with generalized symmetric peripheral neuropathy, a standard 
laboratory evaluation should include a complete blood count, basic 
chemistries including serum electrolytes and tests of renal and hepatic 
function, fasting blood glucose (FBS), HbA1c, urinalysis, thyroid function 
tests, B12, folate, erythrocyte sedimentation rate (ESR), rheumatoid factor, 
antinuclear antibodies (ANA), serum protein electrophoresis (SPEP), and 
urine for Bence Jones protein. An oral glucose tolerance test is indicated in 
patients with painful sensory neuropathies even if FBS and HbA1c are 
normal, as the test is abnormal in about one-third of such patients. Serum 
and urine immunofixation electrophoresis (IFE) are necessary, rather than 
just an SPEP, in patients with a demyelinating neuropathy or if one suspects 
amyloidosis (e.g., severe autonomic symptoms) as an IFE is more sensitive 
at identifying a monoclonal gammopathy. A skeletal survey should be 
performed in patients with acquired demyelinating neuropathies and M-
spikes to look for osteosclerotic or lytic lesions. Patients with monoclonal 
gammopathy should also be referred to a hematologist for consideration of a 
bone marrow biopsy. In addition to the above tests, patients with a 
mononeuropathy multiplex pattern of involvement should have a vasculitis 
workup, including antineutrophil cytoplasmic antibodies (ANCA), 
cryoglobulins, hepatitis serology, Western blot for Lyme disease, HIV, and 
occasionally a cytomegalovirus (CMV), titer. 
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There are many autoantibody panels (various antiganglioside antibodies) 
marketed for screening routine neuropathy patients for a treatable condition. 
These autoantibodies have no proven clinical utility or added benefit beyond 
the information obtained from a complete clinical examination and detailed 
EDx. A heavy metal screen is also not necessary as a screening procedure, 
unless there is a history of possible exposure or suggestive features on 
examination (e.g., severe painful sensorimotor and autonomic neuropathy 
and alopecia—thallium; severe painful sensorimotor neuropathy with or 
without GI disturbance and Mee's lines—arsenic; wrist or finger extensor 
weakness and anemia with basophilic stippling of red blood cells—lead). 
In patients with suspected GBS or CIDP, a lumbar puncture is indicated to 
look for an elevated cerebral spinal fluid (CSF) protein. In idiopathic cases 
of GBS and CIDP, there should not be pleocytosis in the CSF. If cells are 
present, one should consider HIV infection, Lyme disease, sarcoidosis, or 
lymphomatous or leukemic infiltration of nerve roots. Some patients with 
GBS and CIDP have abnormal liver function tests. In these cases, it is 
important to also check for hepatitis B and C, HIV, CMV, and Epstein-Barr 
virus (EBV) infection. In patients with an axonal GBS (by EMG/NCS) or 
those with a suspicious coinciding history (e.g., unexplained abdominal 
pain, psychiatric illness, significant autonomic dysfunction), it is reasonable 
to screen for porphyria. 
In patients with a severe sensory ataxia, a sensory ganglionopathy or 
neuronopathy should be considered. The most common causes of sensory 
ganglionopathies are Sjögren syndrome and a paraneoplastic neuropathy. 
Neuropathy can be the initial manifestation of Sjögren syndrome. Thus, one 
should always inquire about dry eyes and mouth in patients with sensory 
signs and symptoms. Further, some patients can manifest sicca complex 
without full-blown Sjögren syndrome. Thus, patients with sensory ataxia 
should have an senile systemic amyloidosis (SSA) and single strand binding 
(SSB) in addition to the routine ANA. To workup a possible paraneoplastic 
sensory ganglionopathy, anti-neuronal nuclear antibodies (e.g., anti-Hu 
antibodies) should be obtained. These antibodies are most commonly seen 
in patients with small cell carcinoma of the lung but are seen also in breast, 
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ovarian, lymphoma, and other cancers. Importantly, the paraneoplastic 
neuropathy can precede the detection of the cancer, and detection of these 
autoantibodies should lead to a search for malignancy. 
Nerve Biopsies 
Nerve biopsies are now rarely indicated for evaluation of neuropathies. The 
primary indication for nerve biopsy is suspicion for amyloid neuropathy or 
vasculitis. In most instances, the abnormalities present on biopsies do not 
help distinguish one form of peripheral neuropathy from another (beyond 
what is already apparent by clinical examination and the NCS). Nerve 
biopsies should only be done if the NCS studies are abnormal. The sural 
nerve is most commonly biopsied because it is a pure sensory nerve and 
biopsy will not result in loss of motor function. In suspected vasculitis, a 
combination biopsy of a superficial peroneal nerve (pure sensory) and the 
underlying peroneus brevis muscle obtained from a single small incision 
increases the diagnostic yield. Tissue can be analyzed by frozen section and 
paraffin section to assess the supporting structures for evidence of 
inflammation, vasculitis, or amyloid deposition. Semithin plastic sections, 
teased fiber preparations, and electron microscopy are used to assess the 
morphology of the nerve fibers and to distinguish axonopathies from 
myelinopathies. 
Skin Biopsies 
Skin biopsies are sometimes used to diagnose a small-fiber neuropathy. 
Following a punch biopsy of the skin in the distal lower extremity, 
immunologic staining can be used to measure the density of small 
unmyelinated fibers. The density of these nerve fibers is reduced in patients 
with small-fiber neuropathies in whom nerve conduction studies and routine 
nerve biopsies are often normal. This technique may allow for an objective 
measurement in patients with mainly subjective symptoms. However, it 
adds little to what one already knows from the clinical examination and 
EDx. 
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Acquired Neuropathies 
Primary or Al Amyloidosis  
Besides FAP, amyloidosis can also be acquired. In primary or AL 
amyloidosis, the abnormal protein deposition is composed of 
immunoglobulin light chains. AL amyloidosis occurs in the setting of 
multiple myeloma, Waldenström macroglobulinemia, lymphoma, other 
plasmacytomas, or lymphoproliferative disorders, or without any other 
identifiable disease. 
Approximately 30% of patients with AL primary amyloidosis present with a 
polyneuropathy, most typically painful dysesthesias and burning sensations 
in the feet. However, the trunk can be involved and some manifest with a 
mononeuropathy multiplex pattern. CTS occurs in 25% of patients and may 
be the initial manifestation. The neuropathy is slowly progressive, and 
eventually weakness develops along with large-fiber sensory loss. Most 
patients develop autonomic involvement with postural hypertension, 
syncope, bowel and bladder incontinence, constipation, impotence, and 
impaired sweating. Patients generally die from their systemic illness (renal 
failure, cardiac disease). 
The monoclonal protein may be composed of IgG, IgA, IgM, or only free 
light chain. Lambda ( ) is more common than light chain (>2:1) in AL 
amyloidosis. The CSF protein is often increased (with normal cell count), 
and thus the neuropathy may be mistaken for CIDP. Nerve biopsies reveal 
axonal degeneration and amyloid deposition in either a globular or diffuse 
pattern infiltrating the perineurial, epineurial, and endoneurial connected 
tissue and in blood vessel walls. 
The median survival of patients with primary amyloidosis is less than 2 
years, with death usually from progressive congestive heart failure or renal 
failure. Chemotherapy with melphalan, prednisone, and colchicine, to 
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reduce the concentration of monoclonal proteins, and autologous stem cell 
transplantation may prolong survival, but whether the neuropathy improves 
is controversial. 
Diabetic Neuropathy 
Diabetes mellitus (DM) is the most common cause of peripheral neuropathy 
in developed countries. DM is associated with several types of 
polyneuropathy: distal symmetric sensory or sensorimotor polyneuropathy, 
autonomic neuropathy, diabetic neuropathic cachexia, 
polyradiculoneuropathies, cranial neuropathies, and other 
mononeuropathies. Risk factors for the development of neuropathy include 
long-standing, poorly controlled DM and the presence of retinopathy and 
nephropathy. 
Diabetic Distal Symmetric Sensory and Sensorimotor Polyneuropathy 
(DSPN) 
DSPN is the most common form of diabetic neuropathy and manifests as 
sensory loss beginning in the toes that gradually progresses over time up the 
legs and into the fingers and arms. When severe, a patient may develop 
sensory loss in the trunk (chest and abdomen), initially in the midline 
anteriorly and later extending laterally. Tingling, burning, deep aching pains 
may also be apparent. NCS usually show reduced amplitudes and mild to 
moderate slowing of conduction velocities (CVs). Nerve biopsy reveals 
axonal degeneration, endothelial hyperplasia, and, occasionally, 
perivascular inflammation. Tight control of glucose can reduce the risk of 
developing neuropathy or improve the underlying neuropathy. A variety of 
medications have been used with variable success to treat painful symptoms 
associated with DSPN, including antiepileptic medications, antidepressants, 
sodium channel blockers, and other analgesics. 
Diabetic Autonomic Neuropathy 
Autonomic neuropathy is typically seen in combination with DSPN. The 
autonomic neuropathy can manifest as abnormal sweating, dysfunctional 
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thermoregulation, dry eyes and mouth, pupillary abnormalities, cardiac 
arrhythmias, postural hypotension, gastrointestinal abnormalities (e.g., 
gastroparesis, postprandial bloating, chronic diarrhea or constipation), and 
genitourinary dysfunction (e.g., impotence, retrograde ejaculation, 
incontinence). Tests of autonomic function are generally abnormal, 
including sympathetic skin responses and quantitative sudomotor axon 
reflex testing. Sensory and motor NCS generally demonstrate features 
described above with DSPN. 
Diabetic Radiculoplexus Neuropathy (Diabetic Amyotrophy or Bruns-
Garland Syndrome) 
Diabetic radiculoplexus neuropathy is the presenting manifestation of DM 
in approximately one-third of patients. Typically, patients present with 
severe pain in the low back, hip, and thigh in one leg. Rarely, the diabetic 
polyradiculoneuropathy begins in both legs at the same time. Atrophy and 
weakness of proximal and distal muscles in the affected leg become 
apparent within a few days or weeks. The neuropathy is often accompanied 
or heralded by severe weight loss. Weakness usually progresses over several 
weeks or months, but can continue to progress for 18 months or more. 
Subsequently, there is slow recovery but many are left with residual 
weakness, sensory loss, and pain. In contrast to the more typical 
lumbosacral radiculoplexus neuropathy, some patients develop thoracic 
radiculopathy or, even less commonly, a cervical polyradiculoneuropathy. 
CSF protein is usually elevated, while the cell count is normal. ESR is often 
increased. EDx reveals evidence of active denervation in affected proximal 
and distal muscles in the affected limbs and in paraspinal muscles. Nerve 
biopsies may demonstrate axonal degeneration along with perivascular 
inflammation. Patients with severe pain are sometimes treated in the acute 
period with glucocorticoids, although a randomized controlled trial has yet 
to be performed, and the natural history of this neuropathy is gradual 
improvement. 
Diabetic Mononeuropathies or Multiple Mononeuropathies 
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The most common mononeuropathies are median neuropathy at the wrist 
and ulnar neuropathy at the elbow, but peroneal neuropathy at the fibular 
head, and sciatic, lateral femoral, cutaneous, or cranial neuropathies also 
occur. In regard to cranial mononeuropathies, a seventh nerve palsy is most 
common, followed by third nerve, sixth nerve, and, less frequently, fourth 
nerve palsies. Diabetic third nerve palsies are characteristically pupil-
sparing. 
Hypothyroidism 
Hypothyroidism is more commonly associated with a proximal myopathy, 
but some patients develop a neuropathy, most typically carpal tunnel 
syndrome. Rarely, a generalized sensory polyneuropathy characterized by 
painful paresthesias and numbness in both the legs and hands can occur. 
Treatment is correction of the hypothyroidism. 
Sjögren Syndrome 
Sjögren syndrome, characterized by the sicca complex of xerophthalmia, 
xerostomia, and dryness of other mucous membranes, can be complicated 
by neuropathy. Most common is a length-dependent axonal sensorimotor 
neuropathy characterized mainly by sensory loss in the distal extremities. A 
pure small-fiber neuropathy or a cranial neuropathy, particularly involving 
the trigeminal nerve, can also be seen. Sjögren syndrome is also associated 
with sensory neuronopathy/ganglionopathy. Patients with sensory 
ganglionopathies develop progressive numbness and tingling of the limbs, 
trunk, and face in a non-length-dependent manner such that symptoms can 
involve the face or arms more than the legs. The onset can be acute or 
insidious. Sensory examination demonstrates severe vibratory and 
proprioceptive loss leading to sensory ataxia. 
Patients with neuropathy due to Sjögren syndrome may have antinuclear 
antibodies (ANA), SS-A/Ro, and SS-B/La antibodies in the serum but most 
do not. NCS demonstrate reduced amplitudes of sensory studies in the 
affected limbs. Nerve biopsy demonstrates axonal degeneration. 
Nonspecific perivascular inflammation may be present, but only rarely is 
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there necrotizing vasculitis. There is no specific treatment for neuropathies 
related to Sjögren syndrome. When vasculitis is suspected, 
immunosuppressive agents may be beneficial. Occasionally, the sensory 
neuronopathy/ganglionopathy stabilizes or improves with immunotherapy, 
such as IVIg. 
Rheumatoid Arthritis 
Peripheral neuropathy occurs in at least 50% of patients with rheumatoid 
arthritis (RA) and may be vasculitic in nature (Chap. 326). Vasculitic 
neuropathy can present with a mononeuropathy multiplex, a generalized 
symmetric pattern of involvement, or a combination of these patterns. 
Neuropathies may also be due to drugs used to treat the RA (e.g., tumor 
necrosis blockers, leflunomide). Nerve biopsy often reveals thickening of 
the epineurial and endoneurial blood vessels as well as perivascular 
inflammation or vasculitis, with transmural inflammatory cell infiltration 
and fibrinoid necrosis of vessel walls. The neuropathy often is responsive to 
immunomodulating therapies. 
Systemic Lupus Erythematosus (SLE) 
Between 2 and 27% of individuals with SLE develop a peripheral 
neuropathy. Affected patients typically present with a slowly progressive 
sensory loss beginning in the feet. Some patients develop burning pain and 
paresthesias with normal reflexes, and nerve conduction studies suggest a 
pure small-fiber neuropathy. Less common are multiple mononeuropathies 
presumably secondary to necrotizing vasculitis. Rarely, a generalized 
sensorimotor polyneuropathy meeting clinical, laboratory, 
electrophysiologic, and histologic criteria for either GBS or CIDP may 
occur. Immunosuppressive therapy is beneficial in SLE patients with 
neuropathy due to vasculitis. Immunosuppressive agents are less likely to be 
effective in patients with a generalized sensory or sensorimotor 
polyneuropathy without evidence of vasculitis. Patients with a GBS or 
CIDP-like neuropathy should be treated accordingly (Chap. 385). 
Systemic Sclerosis (Scleroderma) 
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A distal symmetric, mainly sensory, polyneuropathy complicates 5–67% of 
scleroderma cases. Cranial mononeuropathies can also develop, most 
commonly of the trigeminal nerve, producing numbness and dysesthesias in 
the face. Multiple mononeuropathies also occur. The EDx and histologic 
features of nerve biopsy are those of an axonal sensory greater than motor 
polyneuropathy. 
Mixed Connective Tissue Disease (MCTD) 
A mild distal axonal sensorimotor polyneuropathy occurs in approximately 
10% of patients with MCTD. 
Sarcoidosis 
The peripheral or central nervous systems are involved in about 5% of 
patients with sarcoidosis. The most common cranial nerve involved is the 
seventh nerve, which can be affected bilaterally. Some patients develop 
radiculopathy or polyradiculopathy. With a generalized root involvement, 
the clinical presentation can mimic GBS or CIDP. Patients can also present 
with multiple mononeuropathies or a generalized, slowly progressive, 
sensory greater than motor polyneuropathy. Some have features of a pure 
small-fiber neuropathy. EDx reveals an axonal neuropathy. Nerve biopsy 
can reveal noncaseating granulomas infiltrating the endoneurium, 
perineurium, and epineurium along with lymphocytic necrotizing angiitis. 
Neurosarcoidosis may respond to treatment with glucocorticoids or other 
immunosuppressive agents. 
Celiac Disease (Gluten-Induced Enteropathy or Non-Tropical Sprue) 
Neurologic complications, particularly ataxia and peripheral neuropathy, are 
estimated to occur in 10% of patients with celiac disease. A generalized 
sensorimotor polyneuropathy, pure motor neuropathy, multiple 
mononeuropathies, autonomic neuropathy, small-fiber neuropathy, and 
neuromyotonia have all been reported in association with celiac disease or 
antigliadin/antiendomysial antibodies. Nerve biopsy may reveal a loss of 
large myelinated fibers. The neuropathy may be secondary to malabsorption 
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of vitamins B12 and E. However, some patients have no appreciable vitamin 
deficiencies. The pathogenic basis for the neuropathy in these patients is 
unclear but may be autoimmune in etiology. The neuropathy does not 
appear to respond to a gluten-free diet. In patients with vitamin B12 or 
vitamin E deficiency, replacement therapy may improve or stabilize the 
neuropathy. 
Inflammatory Bowel Disease 
Ulcerative colitis and Crohn's disease may be complicated by GBS, CIDP, 
generalized axonal sensory or sensorimotor polyneuropathy, small-fiber 
neuropathy, or mononeuropathy. These neuropathies may be autoimmune, 
nutritional (e.g., vitamin B12 deficiency), treatment related (e.g., 
metronidazole), or idiopathic in nature. An acute neuropathy with 
demyelination resembling GBS may occur, particularly in patients treated 
with tumor necrosis factor blockers. 
Uremic Neuropathy 
Approximately 60% of patients with renal failure develop a polyneuropathy 
characterized by length-dependent numbness, tingling, allodynia, and mild 
distal weakness. Rarely, a rapidly progressive weakness and sensory loss 
very similar to GBS can occur that improves with an increase in the 
intensity of renal dialysis or with transplantation. Mononeuropathies can 
also occur, the most common of which is carpal tunnel syndrome. Ischemic 
monomelic neuropathy (see below) can complicate arteriovenous shunts 
created in the arm for dialysis. EDx in uremic patients reveals features of a 
length-dependent, primarily axonal, sensorimotor polyneuropathy. Sural 
nerve biopsies demonstrate a loss of nerve fibers (particularly large 
myelinated nerve fibers), active axonal degeneration, and segmental and 
paranodal demyelination. The sensorimotor polyneuropathy can be 
stabilized by hemodialysis and improved with successful renal 
transplantation. 
Chronic Liver Disease 
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A generalized sensorimotor neuropathy characterized by numbness, 
tingling, and minor weakness in the distal aspects of primarily the lower 
limbs commonly occurs in patients with chronic liver failure. EDx studies 
are consistent with a sensory greater than motor axonopathy. Sural nerve 
biopsy reveals both segmental demyelination and axonal loss. It is not 
known if hepatic failure in isolation can cause peripheral neuropathy, as the 
majority of patients have liver disease secondary to other disorders, such as 
alcoholism or viral hepatitis, which can also cause neuropathy. 
Critical Illness Polyneuropathy 
The most common causes of acute generalized weakness leading to 
admission to a medical intensive care unit (ICU) are GBS and myasthenia 
gravis. However, weakness developing in critically ill patients while in the 
ICU is usually caused by critical illness polyneuropathy (CIP) or critical 
illness myopathy (CIM), or much less commonly, by prolonged 
neuromuscular blockade. From a clinical and EDx standpoint, it can be quite 
difficult to distinguish these disorders. Most specialists suggest that CIM is 
more common. Both CIM and CIP develop as a complication of sepsis and 
multiple organ failure. They usually present as an inability to wean a patient 
from a ventilator. A coexisting encephalopathy may limit the neurologic 
exam, in particular the sensory examination. Muscle stretch reflexes are 
absent or reduced. 
Serum creatine kinase (CK) is usually normal; an elevated serum CK would 
point to CIM as opposed to CIP. NCS reveal absent or markedly reduced 
amplitudes of motor and sensory studies in CIP, while sensory studies are 
relatively preserved in CIM. Needle EMG usually reveals profuse positive 
sharp waves and fibrillation potentials, and it is not unusual in patients with 
severe weakness to be unable to recruit motor unit action potentials. The 
pathogenic basis of CIP is not known. Perhaps circulating toxins and 
metabolic abnormalities associated with sepsis and multiorgan failure 
impair axonal transport or mitochondrial function, leading to axonal 
degeneration. 
Other infectious disease 
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Leprosy, Lyme disease, Diphtheritic neuropathy, HIV, HVZ, 
Cytomegalovirus, Epstein Barr virus, ecc
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ELECTROPHYSIOLOGIC STUDIES OF MUSCLE AND NERVE 
The motor unit is the basic element subserving motor function. It is defined 
as an anterior horn cell, its axon and neuromuscular junctions, and all the 
muscle fibers innervated by the axon. The number of motor units in a 
muscle ranges from approximately 10 in the extraocular muscles to several 
thousand in the large muscles of the legs. There is considerable variation in 
the average number of muscle fibers within the motor units of an individual 
muscle, i.e., in the innervation ratio of different muscles. Thus the 
innervation ratio is <25 in the human external rectus or platysma muscle and 
between 1600 and 1700 in the medial head of the gastrocnemius muscle. 
The muscle fibers of individual motor units are divided into two general 
types by distinctive contractile properties, histochemical stains, and 
characteristic responses to fatigue. Within each motor unit, all of the muscle 
fibers are of the same type. 
Electromyography 
The pattern of electrical activity in muscle [i.e., the electromyogram 
(EMG)], both at rest and during activity, may be recorded from a needle 
electrode inserted into the muscle. The nature and pattern of abnormalities 
relate to disorders at different levels of the motor unit. 
Relaxed muscle normally is electrically silent except in the end plate region, 
but abnormal spontaneous activity occurs in various neuromuscular 
disorders, especially those associated with denervation or inflammatory 
changes in affected muscle. Fibrillation potentials and positive sharp waves 
(which reflect muscle fiber irritability) and complex repetitive discharges 
are most often—but not always—found in denervated muscle and may also 
occur after muscle injury and in certain myopathic disorders, especially 
inflammatory disorders such as polymyositis. After an acute neuropathic 
lesion, they are found earlier in proximal rather than distal muscles and 
sometimes do not develop distally in the extremities for 4–6 weeks; once 
present, they may persist indefinitely unless reinnervation occurs or the 
muscle degenerates so completely that no viable tissue remains. 
Fasciculation potentials (which reflect the spontaneous activity of individual 
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motor units) are characteristic of slowly progressive neuropathic disorders, 
especially those with degeneration of anterior horn cells (such as 
amyotrophic lateral sclerosis). Myotonic discharges—high-frequency 
discharges of potentials derived from single muscle fibers that wax and 
wane in amplitude and frequency—are the signature of myotonic disorders 
such as myotonic dystrophy or myotonia congenita but occur occasionally 
in polymyositis or other, rarer, disorders. 
Slight voluntary contraction of a muscle leads to activation of a small 
number of motor units. The potentials generated by any muscle fibers of 
these units that are within the pickup range of the needle electrode will be 
recorded. The parameters of normal motor unit action potentials depend on 
the muscle under study and age of the patient, but their duration is normally 
between 5 and 15 ms, amplitude is between 200 V and 2 mV, and most are 
bi- or triphasic. The number of units activated depends on the degree of 
voluntary activity. An increase in muscle contraction is associated with an 
increase in the number of motor units that are activated (recruited) and in 
the frequency with which they discharge. With a full contraction, so many 
motor units are normally activated that individual motor unit action 
potentials can no longer be distinguished, and a complete interference 
pattern is said to have been produced. 
The incidence of small, short-duration, polyphasic motor unit action 
potentials (i.e., having more than four phases) is usually increased in 
myopathic muscle, and an excessive number of units is activated for a 
specified degree of voluntary activity. By contrast, the loss of motor units 
that occurs in neuropathic disorders leads to a reduction in number of units 
activated during a maximal contraction and an increase in their firing rate, 
i.e., there is an incomplete or reduced interference pattern. The 
configuration and dimensions of the potentials may also be abnormal, 
depending on the duration of the neuropathic process and on whether 
reinnervation has occurred. The surviving motor units are initially normal in 
configuration but, as reinnervation occurs, they increase in amplitude and 
duration and become polyphasic. 
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Action potentials from the same motor unit sometimes fire with a consistent 
temporal relationship to each other, so that double, triple, or multiple 
discharges are recorded, especially in tetany, hemifacial spasm, or 
myokymia. 
Electrical silence characterizes the involuntary, sustained muscle 
contraction that occurs in phosphorylase deficiency, which is designated a 
contracture. 
EMG enables disorders of the motor units to be detected and characterized 
as either neurogenic or myopathic. In neurogenic disorders, the pattern of 
affected muscles may localize the lesion to the anterior horn cells or to a 
specific site as the axons traverse a nerve root, limb plexus, and peripheral 
nerve to their terminal arborizations. The findings do not enable a specific 
etiologic diagnosis to be made, however, except in conjunction with the 
clinical findings and results of other laboratory studies. 
The findings may provide a guide to the severity of an acute disorder of a 
peripheral or cranial nerve (by indicating whether denervation has occurred 
and the completeness of the lesion) and whether the pathologic process is 
active or progressive in chronic or degenerative disorders such as 
amyotrophic lateral sclerosis. Such information is important for prognostic 
purposes. 
Various quantitative EMG approaches have been developed. The most 
common is to determine the mean duration and amplitude of 20 motor unit 
action potentials using a standardized technique. The technique of macro-
EMG provides information about the number and size of muscle fibers in a 
larger volume of the motor unit territory and has also been used to estimate 
the number of motor units in a muscle. Scanning EMG is a computer-based 
technique that has been used to study the topography of motor unit action 
potentials and, in particular, the spatial and temporal distribution of activity 
in individual units. The technique of single-fiber EMG is discussed 
separately below. 
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Nerve Conduction Studies 
Recording of the electrical response of a muscle to stimulation of its motor 
nerve at two or more points along its course permits conduction velocity to 
be determined in the fastest-conducting motor fibers between the points of 
stimulation. The latency and amplitude of the electrical response of muscle 
(i.e., of the compound muscle action potential) to stimulation of its motor 
nerve at a distal site are also compared with values defined in normal 
subjects. Sensory nerve conduction studies are performed by determining 
the conduction velocity and amplitude of action potentials in sensory fibers 
when these fibers are stimulated at one point and the responses are recorded 
at another point along the course of the nerve. In adults, conduction velocity 
in the arms is normally between 50 and 70 m/s, and in the legs is between 
40 and 60 m/s. 
Nerve conduction studies complement the EMG examination, enabling the 
presence and extent of peripheral nerve pathology to be determined. They 
are particularly helpful in determining whether sensory symptoms are 
arising from pathology proximal or distal to the dorsal root ganglia (in the 
former instance, peripheral sensory conduction studies will be normal) and 
whether neuromuscular dysfunction relates to peripheral nerve disease. In 
patients with a mononeuropathy, they are invaluable as a means of 
localizing a focal lesion, determining the extent and severity of the 
underlying pathology, providing a guide to prognosis, and detecting 
subclinical involvement of other peripheral nerves. They enable a 
polyneuro-pathy to be distinguished from a mononeuropathy multiplex 
when this is not possible clinically, an important distinction because of the 
etiologic implications. Nerve conduction studies provide a means of 
following the progression and therapeutic response of peripheral nerve 
disorders and are being used increasingly for this purpose in clinical trials. 
They may suggest the underlying pathologic basis in individual cases. 
Conduction velocity is often markedly slowed, terminal motor latencies are 
prolonged, and compound motor and sensory nerve action potentials may be 
dispersed in the demyelinative neuropathies (such as in Guillain-Barré 
syndrome, chronic inflammatory polyneuropathy, metachromatic 
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leukodystrophy, or certain hereditary neuropathies); conduction block is 
frequent in acquired varieties of these neuropathies. By contrast, conduction 
velocity is normal or slowed only mildly, sensory nerve action potentials are 
small or absent, and there is EMG evidence of denervation in axonal 
neuropathies such as occur in association with metabolic or toxic disorders. 
The utility and complementary role of EMG and nerve conduction studies 
are best illustrated by reference to a common clinical problem. Numbness 
and paresthesias of the little finger and associated wasting of the intrinsic 
muscles of the hand may result from a spinal cord lesion, C8/T1 
radiculopathy, brachial plexopathy (lower trunk or medial cord), or a lesion 
of the ulnar nerve. If sensory nerve action potentials can be recorded 
normally at the wrist following stimulation of the digital fibers in the 
affected finger, the pathology is probably proximal to the dorsal root ganglia 
(i.e., there is a radiculopathy or more central lesion); absence of the sensory 
potentials, by contrast, suggests distal pathology. EMG examination will 
indicate whether the pattern of affected muscles conforms to radicular or 
ulnar nerve territory, or is more extensive (thereby favoring a plexopathy). 
Ulnar motor conduction studies will generally also distinguish between a 
radiculopathy (normal findings) and ulnar neuropathy (abnormal findings) 
and will often identify the site of an ulnar nerve lesion. The nerve is 
stimulated at several points along its course to determine whether the 
compound action potential recorded from a distal muscle that it supplies 
shows a marked alteration in size or area or a disproportionate change in 
latency, with stimulation at a particular site. The electrophysiologic findings 
thus permit a definitive diagnosis to be made and specific treatment 
instituted in circumstances where there is clinical ambiguity. 
F-Wave Studies 
Stimulation of a motor nerve causes impulses to travel antidromically (i.e., 
toward the spinal cord) as well as orthodromically (to the nerve terminals). 
Such antidromic impulses cause a few of the anterior horn cells to 
discharge, producing a small motor response that occurs considerably later 
than the direct response elicited by nerve stimulation. The F wave so elicited 
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is sometimes abnormal (absent or delayed) with proximal pathology of the 
peripheral nervous system, such as a radiculopathy, and may therefore be 
helpful in detecting abnormalities when conventional nerve conduction 
studies are normal. In general, however, the clinical utility of F-wave 
studies has been disappointing, except perhaps in Guillain-Barré syndrome, 
where they are often absent or delayed. 
H-Reflex Studies 
The H reflex is easily recorded only from the soleus muscle (S1) in normal 
adults. It is elicited by low-intensity stimulation of the tibial nerve and 
represents a monosynaptic reflex in which spindle (Ia) afferent fibers 
constitute the afferent arc and alpha motor axons the efferent pathway. The 
H reflexes are often absent bilaterally in elderly patients or with 
polyneuropathies and may be lost unilaterally in S1 radiculopathies. 
Muscle Response to Repetitive Nerve Stimulation 
The size of the electrical response of a muscle to supramaximal electrical 
stimulation of its motor nerve relates to the number of muscle fibers that are 
activated. Neuromuscular transmission can be tested by several different 
protocols, but the most helpful is to record with surface electrodes the 
electrical response of a muscle to supramaximal stimulation of its motor 
nerve by repetitive (2–3 Hz) shocks delivered before and at selected 
intervals after a maximal voluntary contraction. 
There is normally little or no change in size of the compound muscle action 
potential following repetitive stimulation of a motor nerve at 2–3 Hz with 
stimuli delivered at intervals after voluntary contraction of the muscle for 
about 20–30 s, even though preceding activity in the junctional region 
influences the release of acetylcholine and thus the size of the end-plate 
potentials elicited by a test stimulus. This is because more acetylcholine is 
normally released than is required to bring the motor end-plate potentials to 
the threshold for generating muscle fiber action potentials. In disorders of 
neuromuscular transmission this safety factor is reduced. Thus in 
myasthenia gravis, repetitive stimulation, particularly at a rate of between 2 
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and 5 Hz, may lead to a depression of neuromuscular transmission, with a 
decrement in size of the response recorded from affected muscles. Similarly, 
immediately after a period of maximal voluntary activity, single or 
repetitive stimuli of the motor nerve may elicit larger muscle responses than 
before, indicating that more muscle fibers are responding. This 
postactivation facilitation of neuromuscular transmission is followed by a 
longer-lasting period of depression, maximal between 2 and 4 min after the 
conditioning period and lasting for as long as 10 min or so, during which 
responses are reduced in size. 
Decrementing responses to repetitive stimulation at 2–5 Hz are common in 
myasthenia gravis but may also occur in the congenital myasthenic 
syndromes. In Lambert-Eaton myasthenic syndrome, in which there is 
defective release of acetylcholine at the neuro-muscular junction, the 
compound muscle action potential elicited by a single stimulus is generally 
very small. With repetitive stimulation at rates of up to 10 Hz, the first few 
responses may decline in size, but subsequent responses increase. If faster 
rates of stimulation are used (20–50 Hz), the increment may be dramatic so 
that the amplitude of compound muscle action potentials eventually reaches 
a size that is several times larger than the initial response. In patients with 
botulism, the response to repetitive stimulation is similar to that in Lambert-
Eaton myasthenic syndrome, although the findings are somewhat more 
variable and not all muscles are affected. 
Single-Fiber Electromyography 
This technique is particularly helpful in detecting disorders of 
neuromuscular transmission. A special needle electrode is placed within a 
muscle and positioned to record action potentials from two muscle fibers 
belonging to the same motor unit. The time interval between the two 
potentials will vary in consecutive discharges; this is called the 
neuromuscular jitter. The jitter can be quantified as the mean difference 
between consecutive interpotential intervals and is normally between 10 and 
50 s. This value is increased when neuromuscular transmission is disturbed 
for any reason, and in some instances impulses in individual muscle fibers 
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may fail to occur because of impulse blocking at the neuromuscular 
junction. Single-fiber EMG is more sensitive than repetitive nerve 
stimulation or determination of acetylcholine receptor antibody levels in 
diagnosing myasthenia gravis. 
Single-fiber EMG can also be used to determine the mean fiber density of 
motor units (i.e., mean number of muscle fibers per motor unit within the 
recording area) and to estimate the number of motor units in a muscle, but 
this is of less immediate clinical relevance. 
Blink Reflexes 
Electrical or mechanical stimulation of the supraorbital nerve on one side 
leads to two separate reflex responses of the orbicularis oculi—an ipsilateral 
R1 response having a latency of approximately 10 ms and a bilateral R2 
response with a latency in the order of 30 ms. The trigeminal and facial 
nerves constitute the afferent and efferent arcs of the reflex, respectively. 
Abnormalities of either nerve or intrinsic lesions of the medulla or pons may 
lead to uni- or bilateral loss of the response, and the findings may therefore 
be helpful in identifying or localizing such pathology. 
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PERIPHERAL UREMIC NEUROPATHY 
 
 
Historical Aspects 
The possibility of peripheral neuropathy in patients treated with 
hemodialysis was first raised shortly after the introduction of the first formal 
hemodialysis program.[1] The first clinical documentation of 
neuropathywas provided in 1961 in two young male patients with hereditary 
interstitial nephritis and deafness. The development of neuropathy in these 
cases, how-ever, was attributed to the underlying hereditary disorder, rather 
than viewed as a complication of ESKD. Following this report, Asbury et 
al.[2]  provided extensive clinical and pathological findings in four men 
who developed neuropathy as a consequence of ESKD of varying etiologies. 
All four patients had clinical features of renal disease for many years before 
the development of neuropathy, which manifested as a symmetrical length-
dependent sensorimotor neuropathy. Nerve biopsies established axonal 
degeneration, maximal distally, with sparing of proximal nerve segments 
and nerve roots. Moreover, there was no evidence to suggest nerve 
compression, inflammation, or the superimposition of a systemic disease 
process, such as diabetes or amyloid, leading to the conclusion that the 
development of neuropathy was a consequence of the underlying renal 
disorder. 
 Early clinical neurophysiological investigations in ESKD patients 
demonstrated reductions in motor nerve conduction velocity in symptomatic 
and asymptomatic patients.[3,4] Jebsen et al.,[5] studying the natural history 
of uremic neuropathy, compared clinical and nerve conduction findings in 
patients treated conservatively to those receiving dialysis therapy. Whereas 
the development of neuropathy in the conservativel treated group was 
related to deteriorating renal function, those patients treated with long-term 
dialysis manifested improvement in both clinical and neurophysiological 
parameters. 
 Following these early reports and in light of the increasing use of dialysis 
and renal transplantation therapies, greater attention has been focused on 
uremic neuropathy, with numerous studies reporting high rates of 
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neuropathy in ESKD patients, generally relating the development of 
neuropathy to the severity of renal failure. Of particular note, studies by 
Nielsen [6, 7-10] and Bolton et al.[11,12] in the 1970s demonstrated nerve 
conduction slowing in clinically unaffected nerve segments, with correlation 
between the extent of renal impairment and degree of conduction slowing, 
as well as improvement in neurophysiological parameters following renal 
transplantation. These studies provided clinical data to suggest that a uremic 
toxin was responsible for the development of neuropathy in ESKD patients, 
a hypothesis that was to become a major focus of future neurophysiological 
research in this condition. 
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Incidence and Clinical Features 
Peripheral neuropathy in ESKD generally presents as a distal symmetrical 
polyneuropathy with greater lower-limb than upper-limb involvement. The 
condition is of insidious onset, progressing over months, and has been noted 
to have a male predominance. It generally only develops at glomerular 
filtration rates less than 12 ml/min. [13] The most frequent clinical features 
are those of large-fiber involvement, with paresthesias, reduction in deep 
tendon reflexes, impaired vibration sense, weakness, and muscle wasting 
(Fig. 1). In the 1970s, Nielsen[6] demonstrated the presence of neuropathic 
symptoms in over 50% of patients with ESKD. Other studies have 
demonstrated prevalence rates varying from 60% to 100%, depending on the 
diagnostic criteria applied. [14,15,16,17] Laaksonen et al.[16]122 staged the 
clinical severity of uremic neuropathy in 21 ESKD patients, using a 
modified version of the neuropathy symptom score (NSS) developed by 
Dyck et al.,[18] and combined this assessment with results of nerve 
conduction studies. The NSS quantified symptoms that were grouped into 
three categories to reflect alteration in motor, sensory, and autonomic 
systems. Within each group, further subsets were used to group symptoms 
according to the region affected and the presence of positive or negative 
symptoms. Using the NSS and the staging procedure previously used in 
studies of diabetic patients, 81% of ESKD patients received a diagnosis of 
neuropathy. Stage 1 neuropathy (asymptomatic neuropathy) was diagnosed 
in 19%, stage 2 neuropathy (symptoms nondisabling) was present in 48%, 
and stage 3 neuropathy (disabling symptoms) was noted in 14%. In a more 
recent study,[19] 93% of ESKD patients had neuropathic symptoms on NSS 
testing, with 72% diagnosed with stage 2 neuropathy and 21% with stage 3 
neuropathy, despite all patients meeting currently accepted guidelines of 
dialysis adequacy.143 
 31 
 
Clinical and Neurophysiological Findings in Generalized Uremic 
Neuropathy 
Early studies of uremic neuropathy utilizing nerve biopsy techniques 
revealed prominent axonal degeneration, most severe in the distal parts of 
nerve trunks. Although initial studies suggested that demyelination was a 
significant feature of uremic neuropathy, subsequent reviews demonstrated 
that demyelination was secondary to axonal loss and that proximal segments 
of the nerves were relatively spared.[20-22] These findings supported the 
concept that uremic neuropathy was a dying-back neuropathy, with 
metabolic failure of the neuron causing distal axonal degeneration.55 
Numerous neurophysiological series have been undertaken in patients with 
uremic neuropathy and have demonstrated findings consistent with a 
generalized neuropathy of the axonal type. Early studies focused on motor 
nerve conduction parameters and demonstrated slowing of conduction 
velocity in patients prior to the development of clinical neuropathy. 
Subsequent studies demonstrated abnormalities of nerve conduction with 
generalized slowing in both sensory and motor nerves, accompanied by 
reduction in sensory response amplitudes. Motor response amplitudes tend 
to remain relatively preserved, although abnormalities in lower-limb motor 
nerves were noted in some patients, accompanied by neurogenic changes in 
distal lower-limb muscles on electromyography. In a recent study, 
amplitude of the sural sensory nerve action potential was found to be the 
most sensitive indicator of uremic neuropathy, being reduced in 50% of 
ESKD patients.[19] Other groups have confirmed similar findings, 
demonstrating reductions in sensory and motor response amplitudes in 
addition to abnormalities of late responses.[16,23] 
 Reduction in peroneal nerve motor conduction velocity[24]137 and 
prolongation of tibial F-wave minimum latencies[16]122 have been 
established as sensitive indicators of neuropathy in ESKD patients. 
Prolongation of soleus H reflexes has also been demonstrated in patients 
without clinical evidence of neuropathy, suggesting that this parameter may 
be more sensitive in detecting early neuropathy.[17] 
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 Studies of quantitative sensory testing in ESKD patients have demonstrated 
increased vibratory perception thresholds, most marked in the lower 
limbs,[25] whereas somatosensory-evoked potentials in ESKD patients 
demonstrate abnormalities of conduction along both the distal and proximal 
segments of peripheral somesthetic pathways, but less commonly along 
intracranial sensory pathways.[26,27] A study of single-fiber 
electromyography demonstrated normal fiber densities in motor units of 
ESKD patients.186 This finding suggested that reinnervation, characterized 
by increased fiber density, had failed to occur. However, this was 
accompanied by increased jitter, possibly reflecting peripheral 
demyelination in the setting of axonal degeneration. Early studies of nerve 
excitability, utilizing a limited range of excitability parameters, 
demonstrated an elevated threshold for excitation even when nerve 
conduction values were normal, in addition to demonstrating prolongation 
of absolute and relative refractory periods.[26,28] As a consequence, it was 
concluded that the safety factor for neural transmission at the nodes of 
Ranvier would be lowered. 
 In addition to the slowly progressive sensorimotor axonal neuropathy, a 
more rapidly progressive motor neuropathy has been described. A small 
number of ESKD patients with diabetes have also been shown to develop a 
subacute neuropathy progressing over a few months, with severe muscle 
weakness. In this group of patients, nerve conduction studies may 
demonstrate features of either a demyelinatingor axonal neuropathy. 
Although the presence of diabetes complicates assessment of nerve 
conduction data, the absence of preexisting neuropathic symptoms and the 
clinical improvement noted following dialysis or renal transplantation 
suggest a metabolic basis for the neuropathy, related to the underlying 
ESKD. Analysis of cerebrospinal fluid (CSF) is rarely helpful, as CSF 
protein concentration is frequently elevated in ESKD patients and may 
simulate the albuminocytologic dissociation that is characteristic of 
Guillain–Barre´ syndrome.[15] Small-fiber neuropathy may develop as a 
clinical entity in ESKD patients. Lindblom and Tegner[29] demonstrated 
abnormalities of thermal sensation in 30% of ESKD patients and concluded 
that smallfiber neuropathy may exist as a distinct entity in these patients. 
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Effects of Dialysis and Transplantation on Uremic Neuropathy 
Early reports investigating the effects of hemodialysis on uremic neuropathy 
suggested that some patients with mild neuropathy recovered completely 
with adequate dialysis.[30] In fact, failure to improve was considered to be 
an indictor of insufficient dialysis. These reports, however, did emphasize 
that the extent of improvement was likely to be related to the severity of 
neuropathy and that patients with severe neuropathy wer unlikely to 
experience any significant recovery. More recent studies, however, have 
demonstrated that improvement in neuropathy with dialysis is an uncommon 
event. [31,32,9] Although these studies suggest that dialysis retards the 
progressionof neuropathy in most patients, in some cases a gradual 
deterioration of neuropathy may occur. A comparison of hemodialysis and 
peritoneal dialysis with regard to neuropathy progression has demonstrated 
no significant difference between the two dialysis forms.[4] Renal 
transplantation remains the only known cure for uremic neuropathy,[11,12] 
with clinical improvement in sensory and to a lesser extent, motor function 
occurring within a few days of transplantation. [33] Serial nerve conduction 
studies following transplantation demonstrated a correlation between the 
improvement in nerve conduction and biochemical parameters, suggesting 
that metabolic phenomena may underlie the rapid improvement.156 Recent 
evidences suggests that treatment with erythropoietin (EPO) may prove 
beneficial in ESKD patients with neuropathy[34] as well as for patients with 
neuropathy due to other etiologies.[35,36] Treatment with EPO improved 
motor nerve conduction velocity in ESKD patients, but had no effect on 
sensory indices. In vitro studies have shown that EPO receptors are present 
on Schwann cells and in dorsal root ganglion neurons. Upregulation of EPO 
receptors occurs after axonal injury, mediated by release of nitric oxide, and 
administration of exogenous EPO is associated with reduction in limb 
weakness and neuropathic pain behavior.[37] 
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Dialyzable Toxins and the “Middle Molecule Hypothesis” 
Hegstrom et al.[38] postulated that uremic neuropathy occurred due to 
accumulation of a dialyzable substance on the basis of their observational 
studies that demonstrated improvement in neuropathy in two subjects with 
long-standing ESKD following commencement of dialysis therapy. Later 
studies demonstrated that patients treated with peritoneal dialysis had lower 
rates of uremic neuropathy despite the fact that these patients frequently had 
higher blood urea and creatinine concentrations.[39] The lower neuropathy 
rate in the peritoneal dialysis group was thought to indicate that the 
substance responsible for neuropathy was better dialyzed by the peritoneum 
than by the cellophane membranes used in hemodialysis. On this basis, the 
most likely group of substances was thought to be the “middle molecules,” 
substances with a molecular weight of 300–12,000  
A study using a hemodialysis membrane highly permeable to middle 
molecules also demonstrated a dramatic reduction in the development of 
neuropathy.[40] These early studies, however, were hampered by a number 
of difficulties, not least of which was the inability to measure middle 
molecule levels.10 Another major shortcoming of the hypothesis has been 
the lack of conclusive evidence that any single molecule in the middle 
molecular range is actually neurotoxic. The only middle molecule for which 
some evidence of neurotoxicity exists is PTH, with some studies suggesting 
a link between PTH and the neurological complications of ESKD. PTH has 
been shown to prolong motor nerve conduction velocities in animal 
studies,[41] although human studies of the effect of PTH on peripheral 
nerves have yielded conflicting results, with variable changes in motor 
nerve conduction velocity in patients with ESKD. Despite the shortcomings 
of the middle molecule hypothesis, the hypothesis that a dialyzable toxin 
may be involved in the pathophysiology of this condition remains prevalent. 
More recently, it has been suggested that the following criteria should be 
met in order for a substance to be truly regarded as a uremic neurotoxin: (1) 
it must be an identifiable chemical; (2) it should be elevated in the blood of 
uremi patients; (3) there should be a direct positive relationship between 
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blood level and neurologicaldysfunction; (4) it should cause neurological 
dysfunction in animals at appropriate blood levels; and (5) its removal from 
the blood should abolish the dysfunction.38 The middle molecule 
hypothesis fails to satisfy a number of these criteria, most importantly 
criterion 3, as there is very little evidence to suggest that such molecules are 
actually neurotoxic. Despite the evidence that a dialyzable toxin may 
underlie the development of uremic neuropathy, the mechanism of this 
neurotoxicity remained unclear.  
Nerve excitability techniques provide an indirect assessment regarding the 
activity of a variety of axonal ion channels, energydependent pumps, and 
ion exchange processes activated during the process of impulse conduction. 
Over recent years, nerve excitability properties have been explored in a 
diverse range of neurological conditions including length-dependent uremic 
neuropathy. These studies have examined changes in nerve function that 
occurred in ESKD patients before, during, and after a single session of 
hemodialysis. Measures of nerve function were also assessed in relation to 
changes in serum levels of potential neurotoxins, including K+, urea, and 
‘‘middlemolecules’’ such as parathyroid hormone and b2-microglobulin. 
Using these novel excitability techniques, predialysis excitability 
abnormalities were established to be strongly correlated with serum K+ in 
all studies. Excitability studies also demonstrated that abnormalities of 
nerve function occurred at a level much lower than that required for cardiac 
toxicity, with patients manifesting axonal changes with serum K+ 
concentrations in the high normal range (i.e., 4.9–5.0 mmol ⁄ l). Following 
dialysis there was significant improvement although minor excitability 
abnormalities persisted, suggesting that dialysis alone is insufficient in 
normalizing nerve function. In contrast, the strong correlations noted with 
serum K+ were not demonstrated for any of the ‘‘middle molecules.’’ These 
findings are also supported by studies that investigated the causes of 
weakness and fatigue in ESKD, and demonstrated that abnormalities of K+ 
regulation may underlie muscle fatigue and thereby contribute to exercise 
limitation in ESKD. Potassium satisfies all the criteria that have been 
recently proposed for a substance to be truly regarded as a uremic 
neurotoxin. It is an identifiable chemical that is elevated in the serum of 
 36 
ESKD patients and causes neurological dysfunction in both humans and 
experimental animals. It is also a critical determinant of axonal resting 
membrane potential. Furthermore, excitability studies have demonstrated 
that a direct relationship exists between serum levels of K+ and 
neurophysiological abnormalities and that removal of K+ leads to 
improvement in nerve function. What is the relationship between transient 
changes in nerve function and the chronic irreversible axonal lossthat occurs 
in length-dependent uremic neuropathy? It is important to recognize that 
alterations in axonal membrane potential are unlikely to be transient in 
ESKD patients, particularly given themarked elevations in total body K+, 
which may cause a postdialysis rebound in serum K+ concentration. Such 
persistent elevation in serum K+ would lead to chronic membrane 
depolarization. It is well known that chronic changes in membrane potential 
are harmful to axons and may trigger reverse activation of the Na+⁄Ca2+ 
exchanger, leading to an influx of Ca2+. Such processes may initiate a 
cascade that eventually induces axonal death.[42] 
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EPIDEMIOLOGICAL STUDY 
 
Patients 
 
We investigated all the 225 patients (138 males and 87 females) on RDT in 
two Italian Dialysis Centres (Nephrology, Dialysis and Hypertension -  
Policlinico S. Orsola-Malpighi - Bologna and Nephrology and Dialysis Unit 
- Ospedale S. Croce e Carle - Cuneo). 
Their mean age was 67.8 ± 14.2 years (median age 70 years) with a mean 
dialysis vintage of 56 ± 51.5 months. 
We excluded from the study only 2 amputee patients and 4 patients who 
were affected by severe vascular encephalopathy because of their 
unreliability to the answers to the specific test performed. 
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Materials and Methods 
 
The diagnosis of neuropathy was formulated on the basis of the Michigan 
Neuropathy Score Instrument (MNSI), already validated for the diagnosis of 
diabetic neuropathy [43],  that was applied to all the patients before the mid-
week dialysis session. 
It consists of two parts: a questionnaire for the patient and a physical-
clinical assessment performed by the physician. 
The questionnaire, filled out for each patient, deals with questions about the 
feeling in legs and feet. 
The clinical-physical assessment consists of a series of examinations: a) 
physical assessment of both feet for evidence of excessively dry skin, 
callous formation, fissures…. b) examination of the ankle reflexes using an 
appropriate reflex hammer and directly percussing the Achilles tendon with 
the foot should passively position and slightly dorsiflex to obtain optimal 
stretch of the muscle. If the reflex is absent, the patient is asked to perform 
the Jendrassic maneuver (i.e., hooking the fingers together and pulling); in 
this case the reflex is present with reinforcement. c) vibration sensation 
performed with the great toe unsupported. Vibration sensation is tested 
bilaterally using a 128 Hz tuning fork placed over the dorsum of the great 
toe on the bony prominence of the Distal Interphalangeal (DIP) joint. 
Patients, whose eyes are closed, are asked to indicate when they can no 
longer sense the vibration from the vibrating tuning fork. d) monofilament 
testing: the filament is applied perpendicularly and briefly, (<1 second) with 
an even pressure to the dorsum of the great toe midway between the nail 
fold and the DIP joint without holding the toe directly. When the filament 
bends, the force of 10 grams has been applied. The patient, whose eyes are 
closed, is asked to respond yes if he/she feels the filament. 
For each part of the test the outcome is an ordinal numeric variable (going 
up in steps of 0.5) ranging from a minimum of 0 to a maximum of 1 and the 
final score is the sum of the scores obtained for each part (table 1). 
A final score ≥ 3 at the MNSI was chosen to define the diagnosis of UN in 
accordance with the literature[44] . 
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In order to select the patients who where affected by pure UN, patients 
presenting other potential causes of peripheral neuropathy (alcohol 
consumption, diabetes, liver disease, HCV positivity, hypothyroidism, 
vascular diseases and vasculitis, neoplasia) were excluded from further 
analysis. 
The patients diagnosed as affected by pure UN underwent also a traditional 
electroneurographic study  (ENG). 
ENG was performed by the instrument Synergy Medelec (Oxford 
Instruments, Eynsham, UK). Motor Conduction velocity of sciaticus 
popliteus externus nerve (MCV SPE) and ulnar nerve (MCV ulnar), as well 
as sensory conduction velocity of suralis nerve (sural SCV) and ulnar nerve 
(ulnar SCV) with their sensory nerve action potential (SNAP) and 
compound muscle action potential (cMAP) of both sciaticus popliteus 
externus and ulnar nerve (cMAP SPE and cMAP ulnar) were sampled.  
MCV and cMAP of SPE were obtained through stimulation of the SPE at 
the ankle, 8 cm proximal to the active recording electrode, at the midpoint 
between the medial and lateral malleoli at the top of the ankle, and at the 
knee, just under the fibular head. Sural SCV and SNAP were obtained 
through registration of the lateral skin surface of the ankle by stimulating 
the sural nerve beneath the medial side of the lateral gastrocnemious. SNAP 
was considered not evocable after 10 failed attempts for each leg. Ulnar 
MCV and cMAP  were obtained through  two stimulation points at the 
medial surface of the arm, the first 7 cm  proximal to the active recording 
electrode over the adbuttor of the fifth thunder and the second just below the 
elbow joint. Ulnar SNAP were sampled antidromically  through registration 
of the fifth thunder by stimulating the nerve 14 cm proximal to the active 
registration electrode. 
According to the American Association of Electrodiagnostic Medicine 
(AAEM), we considered obtained values as abnormal when they varied by 
more than 2 standard deviations from the mean normal values [45]. 
For statistical analysis, the correlation between MNSI and the results 
derived from ENG were analyzed by Linear regression and the Fisher exact 
test (Graphpad ® software). 
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Results 
 
Out of the 225 patients in the 2 Centres, 138 (61.3%) reached a score ≥ 3 at 
MNSI and were diagnosed as affected by neuropathy. 
One hundred and one of them (44.9%) however presented pathologies that 
could give rise to secondary forms of neuropathy. In detail: 35 diabetics; 15 
HCV positive patients; 12 with haematological diseases; 6 with diagnosis of 
vasculitis; 74 with obstructive arteriopathy to the lower limbs; 2 affected by 
neoplasia. Some patients presented several concomitant comorbidities. The 
remaining 37 patients (25 males) who reached the score ≥3, were diagnosed 
as affected by UN, corresponding to an overall prevalence of 16.4% of the 
entire population studied (37/225). 
Eighty-seven patients (38.7%) did not reach the score 3, thus were 
considered as not affected by neuropathy, even though 52 of them (23.1%) 
presented pathologies that could potentially give rise to secondary forms of 
neuropathy. Of the remaining 35 patients, 26 (74.3%) were actually 
asymptomatic (score=0), while 9 (25.7% of the group and 4% of the entire 
population) presented an initial subjective symptomatology even though the 
cut-off was < 3 (table 2).  
Near a half of the 37 patients with UN diagnosis were treated with 
conventional hemodialysis (18 pts) while, in the other half, different 
convective-diffusive techniques were applied (9  haemodiafiltration, 6 
acetate-free biofiltration, 2 hemodiafiltration online endogenous reinfusion  
and 2 mid-dilution hemodiafiltration. 
The majority of the 37 patients with  UN referred different symptoms: 
muscle weakness (10 patients), paresthesias (5 patients); 4 presented heavy 
pain related to UN and needed symptomatic therapy (Gabapentin or 
Pramipexole) even if they experienced minimal therapeutic results; 6 
patients were diagnosed as having Restless Leg Syndrome. The quality of 
life of 6 patients was markedly influenced by the presence of the symptoms 
leading to restrictions in their daily activities.  
In the patients without any pathology possibly causing secondary 
neuropathy, a multiple regression analysis was performed to identify the 
potential clinical correlates of UN According to the MNSI score the patients 
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were divided in: score >3 (37 pts) and score <3 (35 pts). A significant  
correlation emerged  between neuropathy and patients’ age (p<0.001), as 
well as male sex (p=0.036).  Instead, we did not find a correlation between 
neuropathy and the underlying nephropaty or the dialysis technique (Table 
3). 
All the 37 patients affected by UN underwent ENG study; 7 studies resulted 
of insufficient quality so only 30 have been utilized to perform statistical 
analysis. 
Both the components of the MNSI (MNSI-Q and MNSI-P) were tested with 
SCV, MCV and SNAP measured by means of the ENG including those 
patients with border-line symptoms. 
A significant correlation (r2=0.3454; p=0.027) was found between MNSI-P 
and SNAP (Figure 1). 
A significant correlation (r2 = 0.1959; p=0.034) was found also between 
MNSI-P and the SCV (Figure 2) but not with the MCV.  
The relationship between question MNSI (MNSI-Q) with CVS, MCV, 
SNAP did not prove significant (p=ns). 
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Discussion 
 
Neuropathy is a common complication that occurs in patients undergoing 
dialysis but few and extremely variable data are known on its prevalence. 
Up to 65% of the incident dialysis patients already present symptoms of 
neuropathy [3,4]. Its prevalence appears to increase with dialysis vintage 
[8]. 
As reported before. according to several studies, the prevalence of 
neuropathy varies from 50 to 100%. This variability probably depends on 
the various methods used for the diagnosis of neuropathy and although UN 
has been known for many years and it is a highly invalidating disease, there 
are few data on its actual  prevalence in RDT patients.  
Our study shows a prevalence of pure UN in this HD population of 16.4%. 
However another small number of patients, (4% of the study population), 
actually presents the clinical symptoms of uremic neuropathy, even though 
without reaching the MNSI score for the diagnosis of UN. This group 
increases the overall prevalence of UN to 20%, meaning that UN is a far 
more frequent problem than previously suspected. 
The diagnosis of UN is based on clinical manifestations and on 
Electromyography or ENG to study the nerve conductivity. A simple, 
reliable and repeatable method to perform is lacking, however. 
MNSI is a non-invasive, simple instrument consisting of a questionnaire 
administered to the patient and of a neurological-clinical examination that 
can be performed by the clinician. It has been validated in the neurological 
field for the screening of diabetic neuropathy. So the lack of specific 
validation in dialysis patients could be considered a study limitation. 
We decided to utilize this instrument for several reasons. From a 
pathophysiological standpoint, diabetic and uremic neuropathy are both of 
metabolic origin, with the difference that diabetic neuropathy is 
characterized by a segmental demyelinization while uremic neuropathy by 
axonal with secondary paranodal demyelinization, but, in both the cases, the 
slowing of motor conduction velocities are similar. From a practical point of 
view MNSI is simple to perform and can be used in routine clinical work. 
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By using this instrument, we found a significant correlation between MNSI–
P and VCS and a better significant correlation between MNSI-P and SNAP. 
This positive result indicates that MNSI, already validated for diabetic 
neuropathy [15], proves to be as a reliable instrument also for the diagnosis 
of UN. Thus, from a prospective point of view it could be considered in 
future a first level analysis for the detection of UN in dialysis patients. 
Although initial studies suggested that demyelination was a significant 
feature of UN, subsequent reviews have demonstrated that demyelination is 
secondary to axonal loss and that proximal segments of the nerve are 
relatively spared, supporting the concept of the ‘dying back’ neuropathy 
with metabolic failure of the neuron causing distal axon degeneration . 
Our result is in line with the pathogenetic hypothesis of UN. In fact, the 
nerve potential amplitudes are in a relationship with the number of excitable 
fibres of the nervous trunk while the conduction velocity is dependent on 
the entity of myelination of the fibres. So we can reasonably accept the 
hypothesis of axonal damage with secondary demyelination. 
Moreover, the correlation found between UN and the patients’ age is in line 
with  the epidemiological data on diabetic neuropathy [22],  and can be 
considered another element in favour of the use of MNSI also in the 
diagnosis of UN.  
The pathophysiology of UN is not well understood but has been attributed 
to one or more toxins retained in uremia not adequately removed by 
dialysis. Some Authors have reported a complete recovery of UN improving 
treatment efficiency. 
In our study UN diagnosis was confirmed in 37 patients; their dialysis 
treatments were very different ranging from conventional dialysis to high 
convective-diffusive techniques. This means that in spite of the great 
progress in the technological aspects of dialysis with the use of high-flux 
membranes and the introduction of convective-diffusive treatment, the 
improvement in the control of UN would seem lower than expected. 
This is in line with the conclusion of some studies demonstrating that an 
improvement in neuropathy with dialysis is uncommon and that, in most 
patients, dialysis can only slow down UN progression . 
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Despite the hypothesis of a ‘toxic’ origin of UN, the exact neurotoxic 
mechanism remains unclear. In fact, the evidence of a neurotoxicity 
determined by middle molecules is poor. At the moment, parathormone 
(PTH, molecular weight 9500 daltons) is the only middle molecule for 
which some evidence of neurotoxicity exists. The neurotoxic effect might be 
due to alterations in membrane excitability by inhibition of the activity of 
the Na/K pump that is of critical importance in maintaining normal ion 
gradients essential for axonal survival. 
New incoming studies show that other molecules could be involved in the 
comprehension of the mechanisms at the basis of the UN. Costigan et al 
demonstrated a correlation between neurologic abnormalities and plasma 
concentration of 3-carboxi-4-metil-5-propyl-2-furanpropionic acid (CMFP), 
one of the urofuranic fatty acids, a strongly lipophilic uremic solute, and one 
of the major  inhibitors of drug protein binding [46]25. 
In consideration of these pathogenetic origins, a rationale actually exists 
towards the use of convection in the dialysis treatment to clear substances in 
the medium weight molecular range.  
However, potassium can also be considered as uremic toxin. Prolonged 
exposure to hyperkaliemia in haemodialysis patients may cause disruption 
of the normal ionic gradients and activate calcium-mediated damaging 
processes leading to axonal loss. 
Traditionally, and in absence of a specific therapy, pharmacological options 
to reduce neuropathy symptoms are represented by benzodiazepine and 
more recently by gabapentin.  Recent evidence suggests a beneficial effect 
of the treatment with erythropoietin (EPO) in end-stage renal disease 
patients with neuropathy as well as in patients with neuropathies due to 
other aetiologies.  
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Conclusions  
 
Independently of the underlying diseases, neuropathy is a very common 
condition in dialysis patients. Uremic neuropathy itself is an underestimated 
pathology in the dialysis population, even though it represents a great 
problem in terms of painful symptomatology, disability and quality of life. 
A clinical-instrumental screening assessment could help to detect the initial 
forms of scarcely symptomatic Uremic Neuropathy for an early therapeutic 
approach. 
MNSI could represent a valid instrument at this purpose, being a simple 
method for the detection of uremic neuropathy that is pathophysiologically 
similar to diabetic neuropathy. Renal physicians should maintain a high 
degree of alertness for detecting and (whenever possible) treat  this  
condition. 
Further multicenter and structured studies are needed to establish whether, 
in a larger population, MNSI can be confirmed as a reliable and simple 
instrument for UN diagnosis.    
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TABLES 
 
Table 1 -  MNSI evaluation score 
 
Score assigned during MNSIa procedureb 
Appearance of feetc  
Ulceration 
Ankle reflexes 
Vibration perception 
Monofilament 
Normal = 0, abnormal = 1 
Absent = 0, present = 1 
Absent = 1, reduced/present with reinforcement = 0.5, present = 0 
Absent = 1, reduced = 0.5, present = 0 
Absent = 1, reduced = 0.5, present = 0 
 
a Michigan neuropathy screening instrument. 
b Maximum total score for each foot is 4 and for both feet is 8. 
c Includes deformity, dry skin, callus, infection and fissures. 
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Table 2 -  population characteristics 
 
Patients: overall number 225 
Patients: score classification Score < 3 (No Neuropathy) Score ≥ 3 (Neuropathy) 
Patients: score results:No(%) 87 (38.7) 138 (61.3) 
Type of Neuropathy 
Potential 
Secondary 
Neuropath
y 
No 
Symptoms 
Initial 
Symptoms 
Pure 
Uremic 
Neuropathy 
Potential 
Secondary 
Neuropathy 
Type of Neuropathy   No (%) 52(23.1) 26(11.6) 9(4) 37(16.4) 101(44.9) 
MNSI score (mean values) 6.5 ± 3.6* 1.2 ± 0.5** 5.07 ± 1.7 6.5 ± 3.6* 
Sex (M/F) (No) 33/19 12/14 5/4 25/12 62/39 
Age (yrs) 65.2±14.8 54.4±15.7 55.4±14.5 72.6±8.6 72.1±11.8 
Dialytic vintage (mths) 54.3±83.6 15.7±38.1 14.5±21.7 53.4±52.7 49.5±67.9 
NAS  No (%) 19 (36.6) 8 (30.8) 2 (22.2) 12 (32.4) 25 (24.8) 
DN   No (%) 10 (19.2) 3 (11.5) 1 (11.1) 0 (0) 27 (26.7) 
GN    No (%) 6 (11.5) 3 (11.5) 0 (0) 7 (18.9) 8 (7.9) 
PKD  No (%) 1 (1.9) 0 (0) 1 (11.1) 2 (5.4) 4 (4) 
IN   No (%) 3 (5.8) 2 (7.7) 3 (33.4) 4 (10.9) 6 (5.9) 
Cause of ESRD 
OT  No (%) 13 (25) 10 (38.5) 2 (22.2) 12 (32.4) 31 (30.7) 
Legend: 
ESRD: end stage renal disease; NAS: nephroangiosclerosis; DN: diabetes nephropathy; GN: glomerulonephritis; 
PKD: polycystic kidney disease; IN: interstitial nephropathy; OT: other  
* MNSI mean value of all patients with possible secondary neuropathy independently of the MNSI score 
** MNSI mean value of all the patients without UN independently of the presence of symptoms. 
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Table 3. Logistic Regression Table of Uremic Neuropathy in the dialysis population having no 
pathology potentially cause of secondary neuropathy 
 
 
Predictor Coef SE Coef Odds Ratio P-value [95% IC] 
Male sex 1.73804 0.827462 5.69 0.036 1.12 28.79 
Age (yrs) 0.145897 0.0393348 1.16 0.000 1.07 1.25 
Dialysis Vintage (mths) 0.0147958 0.0101868 1.01 0.146 0.99 1.04 
Dialytic treatment      
 BD -0.624284 1.31842 0.54 0.636 0.04 7.10 
 HDF -0.448315 1.45130 0.64 0.757 0.04 10.98 
Cause of Nephropathy      
 ESRD 2.41272 2.57564 11.16 0.349 0.07 1738.86 
 GN 1.46968 2.40828 4.35 0.542 0.04 487.81 
 IN 0.982489 2.59487 2.67 0.705 0.02 432.00 
 APKD 1.14865 2.55673 5.91 0.843 0.03 635.86 
 NAS 1.82094 2.45330 6.18 0.458 0.05 757.03 
 OT 2.83950 2.49194 17.11 0.255 0.13 226.33 
 
Legend: 
BD: Bicarbonate Dialysis; HDF: Haemodiafiltration; 
ESRD: end stage renal disease; GN: glomerulonephritis; IN: interstitial nephropathy; APKD: autosomic polycystic kidney 
disease; NAS: nephroangiosclerosis; OT: other. 
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FIGURES 
Figure1 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Relationship between Sensory Nerve Action Potentials (SNAP 
µV) and the score obtained from the Michigan Neuropathy Score Instrument 
physical examination (MNSI_P) (r2 = 0.3454; p=0.027). The study includes 
30 patients with Uremic Neuropathy (UN) diagnosis (score > 3 at MNSI). 
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Figure 2: Relationship between Sensory Conduction Velocity (SCV m/sec) 
and the score obtained from the Michigan Neuropathy Score Instrument 
physical examination (MNSI_P) (r2 = 0.1959; p<0.034). The study includes 
30 patients with Uremic Neuropathy (UN) diagnosis (score > 3 at MNSI). 
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